Between the Lines: Expanding Treatment Options in Retina Diseases with Biosimilars
Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11, and explore the practical implications of biosimilars in the broader real-world context.
The state of wet & dry AMD in 2021
Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.